Organizational Chart International Technology Transfer General Information Career Opportunities


Spacer

 
Licensing & Royalties
spacer
 

Licensing Opportunities

Technology Abstracts

Print This Abstract Apply Questions ?
Use of Endogenous Vertebrate Phytase to Increase Capacity To Utilize Phytic Acid in Livestock Feed

Description of Invention:
This invention discloses the concept of creating transgenic farm animals that secrete a native phytase enzyme into their digestive tracts. It has long been recognized that monogastric animals (e.g. pigs and chickens) do not utilize dietary phosphorus as efficiently as possible. This is because a high percentage of total phosphorus (70% in cereals, 50% in legume seeds) is present as phytic acid and its salts - phytate. Monogastric animals utilize phytate inefficiently because they lack the enzyme phytase in their digestive systems. Phytase liberates the phosphorus from phytate, thereby making dietary phosphorus available to the animals. This has the dual effect of both promoting more efficient growth of the animals, as well as imposing less of an environmental burden in the form of excess phosphorus in water streams.

Use of phytase as a growth feed supplement is well known. However, in the past the focus has always been on adding exogenous phytase to animal feed, or to increase the level of phytase expression in the seeds making up the feed. The inventors' novel concept is to redirect expression of a naturally occurring phytase gene so that the enzyme will be secreted into the intestinal lumen. This will create farm animals that can more efficiently utilize unsupplemented feeds. Another problem with existing phytases that the present invention overcomes is that phytase tends to be unstable during the heat treatment used to process feed. This invention overcomes this limitation because the phytase does not have to be incorporated into feed at all.

Inventors:
Stephen Shears (NIEHS) et al.

Patent Status:
DHHS Reference No. E-139-2000/0 --
U.S. Patent No. 7,351,580 issued 01 Apr 2008

Portfolios:
Gene Based Therapies

Gene Based Therapies -Therapeutics-Other
Gene Based Therapies -Therapeutics


For Additional Information Please Contact:
Sury Vepa PhD
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-5020
Email: vepas@mail.nih.gov
Fax: 301/402-0220


Web Ref: 462

Updated: 4/01

 

 
 
Spacer